Back to Search
Start Over
Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.
- Source :
-
Blood advances [Blood Adv] 2019 Jan 22; Vol. 3 (2), pp. 184-186. - Publication Year :
- 2019
- Subjects :
- Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Clinical Trials, Phase III as Topic
Drug Resistance
Follow-Up Studies
Graft vs Host Disease diagnosis
Graft vs Host Disease etiology
Graft vs Host Disease mortality
Humans
Immunosuppressive Agents administration & dosage
Immunosuppressive Agents adverse effects
Kaplan-Meier Estimate
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Steroids therapeutic use
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Graft vs Host Disease drug therapy
Immunosuppressive Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2473-9537
- Volume :
- 3
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Blood advances
- Publication Type :
- Editorial & Opinion
- Accession number :
- 30670534
- Full Text :
- https://doi.org/10.1182/bloodadvances.2018028282